StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Matinas BioPharma's free cash flow for the twelve months ending Dec 31, 2023 was -$15.50M. For fiscal 2023 it was -$15.50M. The highest annual figure on record is -$3.08M in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$15.50M–
FY2022Dec 31, 2022-$20.05M–
FY2021Dec 31, 2021-$15.48M–
FY2020Dec 31, 2020-$17.37M–
FY2019Dec 31, 2019-$14.50M–
FY2018Dec 31, 2018-$10.86M–
FY2017Dec 31, 2017-$12.40M–
FY2016Dec 31, 2016-$6.12M–
FY2015Dec 31, 2015-$7.89M–
FY2014Dec 31, 2014-$8.25M–
FY2013Dec 31, 2013-$3.08M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$4.58M–
Q3 FY2023Sep 30, 2023-$4.44M–
Q4 FY2022Dec 31, 2022-$4.34M–
Q3 FY2022Sep 30, 2022-$5.22M–
Q2 FY2022Jun 30, 2022-$5.19M–
Q1 FY2022Mar 31, 2022-$5.30M–
Q4 FY2021Dec 31, 2021-$3.99M–
Q3 FY2021Sep 30, 2021-$5.97M–
Q4 FY2020Dec 31, 2020-$4.31M–
Q3 FY2020Sep 30, 2020-$5.23M–
Q2 FY2020Jun 30, 2020-$3.17M–
Q1 FY2020Mar 31, 2020-$4.67M–
Q4 FY2019Dec 31, 2019-$4.90M–
Q3 FY2019Sep 30, 2019-$4.15M–
Q2 FY2019Jun 30, 2019-$2.41M–
Q1 FY2019Mar 31, 2019-$3.04M–
Q4 FY2018Dec 31, 2018-$2.62M–
Q3 FY2018Sep 30, 2018-$2.91M–
Q2 FY2018Jun 30, 2018-$2.42M–
Q1 FY2018Mar 31, 2018-$2.91M–
Q4 FY2017Dec 31, 2017-$2.03M–
Q3 FY2017Sep 30, 2017-$2.82M–
Q4 FY2016Dec 31, 2016-$2.12M–
Q3 FY2016Sep 30, 2016-$1.37M–

More Matinas BioPharma figures

See a number that looks wrong?